Poster session will highlight potential of ZL-1218 to modulate tumor microenvironment and regulate anticancer immune response in advanced solid tumors
Trial update demonstrates the advancement of company’s robust, internal global oncology pipeline
SHANGHAI, China & CAMBRIDGE, MA, USA I August 27, 2024 I Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from a Phase 1 study of ZL-1218, the company’s anti-CCR8 antibody, will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13-17, 2024, in Barcelona, Spain. The preliminary results from the ongoing dose-escalation clinical trial (NCT05859464) will highlight the potential of ZL-1218 to reduce regulatory T cells and modulate T-cell function in the tumor microenvironment (TME) of advanced solid tumors.
ZL-1218 is a humanized monoclonal antibody with an enhanced Fc region that targets CCR8, a chemokine receptor selectively expressed on tumor-associated regulatory T cells (Treg) and may enhance antitumor immune response by depletion of CCR8+ Treg cells via antibody-dependent cellular cytotoxicity activity. ZL-1218 offers potential as a novel therapeutic to treat solid tumors. Enrollment is ongoing in the global Phase 1 study of ZL-1218 as a single agent and in combination with pembrolizumab in patients with advanced solid tumor malignancies.
“The ability to overcome the complexities of the tumor microenvironment are critical to improving patient outcomes in cancer immunotherapy,” said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. “The reduction of suppressive tumor-associated regulatory T cells by ZL-1218 offers promise to re-stimulate the immune attack on advanced solid tumors. We look forward to sharing preliminary results from our Phase 1 study at ESMO 2024.”
Details regarding the Zai Lab poster presentation at ESMO 2024 are as follows:
Title: Preliminary Clinical PK and PD analysis of a Phase 1 Study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presentation Number: 1008P
Presenter: Oriol Mirallas, Medical Oncology Specialist, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Date: Saturday, September 14, 2024
Location: Fira Barcelona Gran Via
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
SOURCE: Zai Lab
Post Views: 2,272
Poster session will highlight potential of ZL-1218 to modulate tumor microenvironment and regulate anticancer immune response in advanced solid tumors
Trial update demonstrates the advancement of company’s robust, internal global oncology pipeline
SHANGHAI, China & CAMBRIDGE, MA, USA I August 27, 2024 I Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from a Phase 1 study of ZL-1218, the company’s anti-CCR8 antibody, will be presented in a poster session at the European Society for Medical Oncology (ESMO) Congress 2024 taking place September 13-17, 2024, in Barcelona, Spain. The preliminary results from the ongoing dose-escalation clinical trial (NCT05859464) will highlight the potential of ZL-1218 to reduce regulatory T cells and modulate T-cell function in the tumor microenvironment (TME) of advanced solid tumors.
ZL-1218 is a humanized monoclonal antibody with an enhanced Fc region that targets CCR8, a chemokine receptor selectively expressed on tumor-associated regulatory T cells (Treg) and may enhance antitumor immune response by depletion of CCR8+ Treg cells via antibody-dependent cellular cytotoxicity activity. ZL-1218 offers potential as a novel therapeutic to treat solid tumors. Enrollment is ongoing in the global Phase 1 study of ZL-1218 as a single agent and in combination with pembrolizumab in patients with advanced solid tumor malignancies.
“The ability to overcome the complexities of the tumor microenvironment are critical to improving patient outcomes in cancer immunotherapy,” said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. “The reduction of suppressive tumor-associated regulatory T cells by ZL-1218 offers promise to re-stimulate the immune attack on advanced solid tumors. We look forward to sharing preliminary results from our Phase 1 study at ESMO 2024.”
Details regarding the Zai Lab poster presentation at ESMO 2024 are as follows:
Title: Preliminary Clinical PK and PD analysis of a Phase 1 Study of ZL-1218, a humanized anti-CCR8 IgG1 antibody, in patients with advanced solid tumors
Presentation Number: 1008P
Presenter: Oriol Mirallas, Medical Oncology Specialist, Vall d’Hebron Institute of Oncology, Barcelona, Spain
Date: Saturday, September 14, 2024
Location: Fira Barcelona Gran Via
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
SOURCE: Zai Lab
Post Views: 2,272
